Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): Correlation with survival

Annals of Surgical Oncology

Volumn 5, Issue 7, 1998, Pages 595-602

  Hsueh, Eddy C ^a   Famatiga, Estela ^a   Gupta, Rishab K ^a   Qi, Karen ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Complement dependent cytotoxicity; Humoral response; Regional melanoma; Vaccine

Indexed keywords

MELANOMA VACCINE;

ARTICLE; CANCER SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; TREATMENT OUTCOME;

EID: 0031785553     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303828     Document Type: Article

References (23)

1. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;46:225-44.
2. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic melanoma. W Engl J Med 1985;313:1485-92.
3. Dorval T, Palangie T, Jouve M, et al. Clinical phase II trial of recombinant DNA Interferon (interferon alpha-2b) in patients with metastatic melanoma. Cancer 1986;58:215-8.
4. Legha SS, Papadopoulos NE, Plager C, Ring S, Chawla SP, Evans LM, Benjamin RS. Clinical evaluation of recombinant Interferon alpha-2b (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 1987;5:1240-6.
5. Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ. Treatment of metastatic malignant melanoma with recombinant interferon alpha-2. Immunobiology 1986:172:275-82.
6. Parkinson DR, Abrams JS, Wiernik PH, et al. Interieukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 1990;8:1650-6.
7. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-80.
8. Dutcher JP, Creekmore S, Weiss GR, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989:7:477-85.
9. Ferrone S. Human tumor-associated antigen mimicry by antiidiotypic antibodies: immunogenicity and clinical trials in patients with solid tumors. Ann NY Acad Sci 1993;690:214-24.
10. Berd D, Maguire HC Jr, Mastrangelo MJ. Treatment of human melanoma with a hapten-modifted autologous vaccine. Ann NY Acad Sci 1993;690:147-52.
11. Mitchell MS, Harel W, Kan-Mitchell J, et al. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann NY Acad Sci 1993;690:153-66.
12. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major hislocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93:15388-93.
13. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992:216:463-82.
14. Jones RC, Kelley M, Gupta RK, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996;3:437-45.
15. Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in patients receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16:2913-20.
16. 3 IgM antibody induced by polyvalent melanoma cell vaccine (PMCV) is significantly correlated with survival of patients with regional metastatic melanoma. Proc Am Assoc Cancer Res 1998;38:2516.
17. Renk CM, Gupta RK, Irie RF, Morton DL. Comparison of the techniques used for monitoring humoral immunity in cancer patients. J Surg Oncol 1982;19:155-61.
18. Pellegrino MA, Ferrone S, Reisfeld RA, Irie RF, Golub SH. Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma. Cancer 1977;40:36-41.
19. Lewis MG, Ikonopisov RL, Nairn RC, Phillips TM, Fairley GH, Bodenham DC, Alexander P. Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J 1969;3:547-52.
20. Bodurtha AJ, Chee DO, Laucius JF, Mastrangelo MJ, Prehn RT, Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res 1975;35:189-93.
21. Canevari S, Fossati G, Della Porta G, Balzarini GP. Humoral cytotoxicity in melanoma patients and its correlation with the extent and course of the disease, Int J Cancer 1975;16:722-9.
22. Ferrone S, Pellegrino MA. Cytotoxic antibodies to cultured melanoma cells in the sera of melanoma patients. J Natl Cancer Inst 1977;58:1201-4.
23. We RF, Irie K, Morton DL. A membrane antigen common to human cancer and fetal brain tissues. Cancer Res 1976;36:3510-7.